









































Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3	Regulatory Status
Magrolimab + Azacitidine	CD47 antibody	MDS				 FortySeven ¹	  
AFM13	CD30/CD16A bispecific engager	PTCL				 AFFIMED	
Pelabresib + Ruxolitinib	BET small molecule	MPN				 Constellation ² PHARMACEUTICALS	 
Magrolimab + Rituximab	CD47 antibody	DLBCL			 FortySeven ¹		
Cusatuzumab + Azacitidine	CD70 antibody	AML			 argenx		
Ziftomenib	Menin small molecule	AML: NPM1 mutant & KMT2A rearranged		 KURA ³ ONCOLOGY SUTRO BIOPHARMA			
STRO-001	CD74 antibody drug conjugate	NHL/MM		 X4 PHARMACEUTICALS			
Mavorixafor + Ibrutinib	CXCR4 small molecule	CXCR4 & MYD88 double mutant Waldenström's		 IMMUNE-ONC Therapeutics			
IO-202	LILRB4 antibody	AML/CMML		 RYU THERAPEUTICS			 
ICT01	BTN3A antibody	heme malignancies		 ImCheck Therapeutics			
PVX-410 + ACY-241 +/- Len	XBP1/CD138/CS1 vaccine	Smoldering myeloma		 OncoPep			
NEXI-001	T cell therapy	AML		 NexImmune			
NEXI-002	T cell therapy	MM		 NexImmune			
BTX-1188	GSPT1 + IKZF1/3 degrader	AML/NHL		 biotheryx			
CB-010	CD19/PD1 KO allogeneic CAR	NHL		 CARIBOU BIOSCIENCES			
KT-333	STAT3 degrader	PTCL/CTCL/LGL-L		 KYMERA			
KT-413	IRAKiMiD degrader	MYD88 mutant DLBCL		 KYMERA			
Bexmarilimab	Clever-1 antibody	AML/MDS		 FARON			
IMT-009	CD161 antibody	NHL	 Immunitas THERAPEUTICS				
TBD	<i>in vivo</i> CAR-X	TBD	 ABINTUS				
TBD	CAR macrophage	TBD	 carisma THERAPEUTICS				

 Orphan Drug Designation
 Fast Track Designation
 Breakthrough Therapy Designation

1: Acquired by Gilead ♦ 2: Acquired by Morphosys ♦ 3: Licensed from University of Michigan